Get Updates & Request a Rep A NEW ADMINISTRATION

ALS Expert Video Library

Learn more about RADICAVA® (edaravone) for the treatment of ALS through a series of educational videos.

Expert Experiences

Neurologists who specialize in the treatment of ALS share their thoughts on RADICAVA® and discuss their experience prescribing treatment.

The Efficacy of RADICAVA®

Said Beydoun, MD, FAAN, discusses clinical trial results of RADICAVA®, his use of the ALSFRS-R with his patients, and the challenges that have faced previous ALS clinical trials and how newer clinical trials are addressing them.

These videos are sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA). The speaker is presenting on behalf of, and has received compensation from MTPA.

testimonial video of Dr. Beydoun discussing RADICAVA® (edaravone)

The Efficacy of RADICAVA®

Physician-Patient Treatment Discussions

Physician-Patient Treatment Discussions

testimonial video of Dr. Hayat discussing RADICAVA® (edaravone)

Considerations When Prescribing

testimonial video of Dr. Holmlund discussing RADICAVA® (edaravone)

Safety and Personal Experience When Prescribing

Peer Perspective on Prescribing RADICAVA® (edaravone)

Peer Perspective on Prescribing RADICAVA® (edaravone)

testimonial video of Dr. Holmlund discussing RADICAVA® (edaravone)

Incorporating RADICAVA® Into Your Treatment Considerations

Patient Selection for RADICAVA® (edaravone)

Patient Selection for RADICAVA® (edaravone)


A panel of ALS experts discuss the benefits, risks, and appropriate uses of RADICAVA®.

Pivotal Trial in ALS

Review information on the pivotal trial of RADICAVA® in ALS, including the clinical development program, key inclusion criteria, and baseline patient characteristics.

moderator discussing RADICAVA® (edaravone)

Pivotal Trial in ALS

presentation video of Dr. Jackson discussing RADICAVA® (edaravone)

Efficacy and Safety

moderator, Dr. Jackson, and Dr. Katz discussing RADICAVA® (edaravone)

ALS Functional Rating Scale–Revised


Important Safety Information

Hypersensitivity Reactions

Radicava® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.


Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or


Radicava® is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Please see full Prescribing Information.

For more information about RADICAVA®, call 1-888-292-0058.